載入...
Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
BACKGROUND: Canine cutaneous T‐cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC‐1101 (formerly known as GS‐9219) has shown efficacy in dogs with multicentric lymphoma. One of the observed adverse effects with this dr...
Na minha lista:
| 發表在: | J Vet Intern Med |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4895598/ https://ncbi.nlm.nih.gov/pubmed/25274443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvim.12429 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|